GH21 and D-1553 for KRAS G12C advanced solid tumors
Part of Cancer clinical trials.
This trial tests a combination of two drugs, GH21 and D-1553, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination works better than each drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of advanced solid tumor with a specific mutation called KRAS G12C
- You need to be 18 years old or older
- You must be well enough to do daily activities (ECOG score 0 or 1)
- You must have at least one tumor that can be measured on scans
- No serious heart problems in the past 6 months, and your heart function must be normal
- No active infections requiring treatment, and no severe drug allergies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted pills (GH21 and D-1553) for people with advanced solid tumors that have a specific KRAS G12C mutation, especially those who have already tried another KRAS G12C inhibitor. The goal is to see if the combo can shrink tumors more effectively.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This trial tests a new targeted drug, HS-10529, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth in patients who have already tried standard therapies.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
This study tests a new drug called HS-10541 that targets a specific genetic change (KRAS G12C mutation) found in some advanced cancers. The drug may be given alone or combined with other cancer treatments to see if it can slow or shrink tumors.
Hear when a new Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.